# US 2023/0405143 A1 · Tyrosine-based antibody conjugates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0405143 A1
- Document ID: US20230405143A1
- Status: Published application
- Kind: A1
- Application number: 18/320,403
- Filed: 2023-05-19
- Published: 2023-12-21
- Earliest claimed: 2020-11-20
- Applicants: Synaffix B.V.
- Inventors: Floris Louis VAN DELFT; Jorick Julian BRUINS; Hendrik Bauke ALBADA; Maria Antonia WIJDEVEN
- Web page: https://patentgrep.com/patent/US20230405143A1

## CPC

- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 47/68031: {the drug being an auristatin}
- A61K 47/68035: {the drug being a pyrrolobenzodiazepine}
- A61K 47/6813: {the drug being a peptidic cytokine, e.g. an interleukin or interferon}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6855: {the tumour determinant being from breast cancer cell}
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A process for preparing a glycoprotein-conjugate is provided, comprising: (a) providing an N-glycoprotein having an exposed tyrosine residue, wherein the exposed tyrosine residue is located within 10 amino acids of an N-glycosylation site, but the N-glycosylation site has been modified such that the glycoprotein does not contain a glycan longer than two monosaccharide residues within 10 amino acids of the exposed tyrosine residue; (b) converting the phenol moiety of the exposed tyrosine residue into an ortho-quinone moiety by contacting the glycoprotein with an oxidative enzyme capable of oxidizing tyrosine; and (c) reacting the ortho-quinone moiety with an alkene or alkyne compound via a [4+2] cycloaddition, wherein the compound comprises a (hetero)cycloalkene or (hetero)cycloalkyne moiety and (i) a chemical handle to further modify the compound with a payload, or (ii) a payload. The resulting glycoprotein-conjugates and pharmaceutical compositions and methods of treatment comprising same are also disclosed.

## Claims

### Claim 1

A process for preparing a glycoprotein-conjugate, comprising:
(a) providing an N-glycoprotein having an exposed tyrosine residue, wherein the exposed tyrosine residue is located within 10 amino acids of an N-glycosylation site, but the N-glycosylation site has been modified such that the glycoprotein does not contain a glycan longer than two monosaccharide residues within 10 amino acids of the exposed tyrosine residue;
(b) converting the phenol moiety of the exposed tyrosine residue into an ortho-quinone moiety by contacting the glycoprotein with an oxidative enzyme capable of oxidizing tyrosine;
(c) reacting the ortho-quinone moiety with an alkene or alkyne compound via a [4+2]cycloaddition, wherein the compound comprises a (hetero)cycloalkene or (hetero)cycloalkyne moiety and (i) a chemical handle to further modify the compound with a payload, or (ii) a payload.

### Claim 2 (depends on 1)

The process according to claim 1, wherein the exposed tyrosine residue is located within 5 amino acids of the N-glycosylation site.

### Claim 3 (depends on 1)

The process according to claim 1, wherein the N-glycoprotein having an exposed tyrosine residue is provided by:
(a1) subjecting an N-glycoprotein to deglycosylation by contacting it with an amidase to obtain an N-glycoprotein from which the glycan is removed; or
(a2) subjecting an N-glycoprotein to trimming by contacting it with an endoglycosidase, to form an N-glycoprotein having a glycan of structure -GlcNAc(Fuc)b, wherein b is 0 or 1; or
(a3) providing a mutated N-glycoprotein wherein the glycosylated asparagine is replaced by a non-glycosylated amino acid.

### Claim 4 (depends on 3)

The process according to claim 3, wherein the amidase is PNGase F.

### Claim 5 (depends on 1)

The process according to claim 1, wherein the oxidative enzyme is tyrosinase or (poly)phenol oxidase.

### Claim 6 (depends on 1)

The process according to claim 1, wherein (b) and (c) are performed in one-pot, by contacting the N-glycoprotein simultaneously with the oxidative enzyme and the alkene or alkyne compound.

### Claim 7 (depends on 1)

The process according to claim 1, wherein the alkene or alkyne compound has a structure (3a) or (3b)
wherein:
Q1 is a (hetero)cycloalkene or (hetero)cycloalkyne moiety;
L is a linker;
x is an integer in the range of 1-4;
Q2 is a chemical handle that is reactive towards an appropriately functionalized payload but not towards Q1;
D is a payload.

### Claim 8 (depends on 1)

The process according to claim 1, wherein Q1 is a (hetero)cycloalkyne according to structure (Q1):
wherein:
R15 is independently selected from the group consisting of hydrogen, halogen, —OR16, —NO2, —CN, —S(O)2R16, —S(O)3(−), C1-C24 alkyl groups, C6-C24 (hetero)aryl groups, C7-C24 alkyl(hetero)aryl groups and C7-C24 (hetero)arylalkyl groups and wherein the alkyl groups, (hetero)aryl groups, alkyl(hetero)aryl groups and (hetero)arylalkyl groups are optionally substituted, wherein two substituents R15 may be linked together to form an optionally substituted annulated cycloalkyl or an optionally substituted annulated (hetero)arene substituent, and wherein R16 is independently selected from the group consisting of hydrogen, halogen, C1-C24 alkyl groups, C6-C24 (hetero)aryl groups, C7-C24 alkyl(hetero)aryl groups and C7-C24 (hetero)arylalkyl groups;
Y2 is C(R31)2, O, S, S(+)R31, S(O)R31, S(O)═NR31 or NR31, wherein S(+) is a cationic sulphur atom counterbalanced by B(−), wherein B(−) is an anion, and wherein each R31 individually is R15 or a connection with Q2 or D, connected via L;
u is 0, 1, 2, 3, 4 or 5;
u′ is 0, 1, 2, 3, 4 or 5, wherein u+u′=4, 5, 6, 7 or 8;
v=an integer in the range 8-16.

### Claim 9 (depends on 8)

The process according to claim 8, wherein Q1 is selected from the group consisting of (Q2)-(Q20):
wherein B(−) is an anion.

### Claim 10 (depends on 9)

The process according to claim 9, wherein Q1 is a cyclooctyne according to structure (Q42):
wherein:
R15 is independently selected from the group consisting of hydrogen, halogen, —OR16, —NO2, —CN, —S(O)2R16, —S(O)3(−), C1-C24 alkyl groups, C5-C24 (hetero)aryl groups, C7-C24 alkyl(hetero)aryl groups and C7-C24 (hetero)arylalkyl groups and wherein the alkyl groups, (hetero)aryl groups, alkyl(hetero)aryl groups and (hetero)arylalkyl groups are optionally substituted, wherein two substituents R15 may be linked together to form an optionally substituted annulated cycloalkyl or an optionally substituted annulated (hetero)arene substituent, and wherein R16 is independently selected from the group consisting of hydrogen, halogen, C1-C24 alkyl groups, C6-C24 (hetero)aryl groups, C7-C24 alkyl(hetero)aryl groups and C7-C24 (hetero)arylalkyl groups;
R18 is independently selected from the group consisting of hydrogen, halogen, C1-C24 alkyl groups, C6-C24 (hetero)aryl groups, C7-C24 alkyl(hetero)aryl groups and C7-C24 (hetero)arylalkyl groups;
R19 is selected from the group consisting of hydrogen, halogen, C1-C24 alkyl groups, C6-C24 (hetero)aryl groups, C7-C24 alkyl(hetero)aryl groups and C7-C24 (hetero)arylalkyl groups, the alkyl groups optionally being interrupted by one of more hetero-atoms selected from the group consisting of O, N and S, wherein the alkyl groups, (hetero)aryl groups, alkyl(hetero)aryl groups and (hetero)arylalkyl groups are independently optionally substituted, or R19 is a second occurrence of Q1 or D connected via a spacer moiety; and
I is an integer in the range 0 to 10;
or wherein Q1 is a (hetero)cyclooctyne according to structure (Q43):
wherein
R15 is independently selected from the group consisting of hydrogen, halogen, —OR16, —NO2, —CN, —S(O)2R16, —S(O)3(−), C1-C24 alkyl groups, C5-C24 (hetero)aryl groups, C7-C24 alkyl(hetero)aryl groups and C7-C24 (hetero)arylalkyl groups and wherein the alkyl groups, (hetero)aryl groups, alkyl(hetero)aryl groups and (hetero)arylalkyl groups are optionally substituted, wherein two substituents R15 may be linked together to form an optionally substituted annulated cycloalkyl or an optionally substituted annulated (hetero)arene substituent, and wherein R16 is independently selected from the group consisting of hydrogen, halogen, C1-C24 alkyl groups, C6-C24 (hetero)aryl groups, C7-C24 alkyl(hetero)aryl groups and C7-C24 (hetero)arylalkyl groups;
Y is N or CR15;
or wherein Q1 is a heterocycloheptyne according to structure (Q37):

### Claim 11 (depends on 1)

The process according to claim 1, wherein Q1 is a (hetero)cycloalkene selected from the group consisting of, optionally substituted, (hetero)cyclopropenyl group, (hetero)cyclobutenyl group, a norbornene group, a norbornadiene group, trans-(hetero)cycloheptenyl group, trans-(hetero)cyclooctenyl group, trans-(hetero)cyclononenyl group or trans-(hetero)cyclodecenyl group.

### Claim 12 (depends on 11)

The process according to claim 11, wherein Q1 is selected from the group consisting of (Q44)-(Q56):
wherein Y3 is selected from C(R24)2, NR24 or O, wherein each R24 is individually hydrogen, C1-C6 alkyl or is connected to L, optionally via a spacer, and the bond labelled is a single or double bond, and the R group(s) on Si in (Q50) and (Q51) is alkyl or aryl.

### Claim 13 (depends on 1)

The process according to claim 1, wherein the compound comprises (i) a chemical handle to further modify the compound with a payload, and the process further comprises:
(d) subjecting the chemical handle, preferably Q2, of the glycoprotein obtained in step (c) to a conjugation reaction with a payload having structure F2-D or F2-L2-(D)x, wherein F2 is reactive towards the chemical handle, L2 is a linker and x is an integer in the range of 1-4.

### Claim 14 (depends on 13)

The process according to claim 13, wherein the chemical handle is Q2.

### Claim 15 (depends on 1)

The process according to claim 1, wherein the payload D is selected from the group consisting of an active substance, a reporter molecule, a polymer, a solid surface, a hydrogel, a nanoparticle, a microparticle and a biomolecule.

### Claim 16

A glycoprotein-conjugate according to structure (1a) or (1b):
wherein:
Pr is an N-glycoprotein;
Z1 comprises structure (Za) or (Zb):
wherein the carbon labelled with * is directly connected to the peptide chain of the glycoprotein at an amino acid located within 10 amino acids of an N-glycosylation site, which has been modified such that the glycoprotein does not contain a glycan longer than two monosaccharide residues within 10 amino acids of the amino acid residue, and both of the carbon atoms labelled with ** are connected to L, and the bond depicted as is a single bond or a double bond;
L is a linker;
x is an integer in the range of 1-4;
y is an integer in the range of 1-4;
Q2 is a chemical handle that is reactive towards an appropriately functionalized payload;
D is a payload.

### Claim 17 (depends on 16)

The glycoprotein-conjugate according to claim 16, wherein Z1 has structure:
wherein:
the carbon labelled with * is directly connected to the peptide chain of the glycoprotein and the bond labelled with ** is connected to L, and the bond depicted as is a single bond or a double bond;
R15 is independently selected from the group consisting of hydrogen, halogen, —OR16, —NO2, —CN, —S(O)2R16, —S(O)3(−), C1-C24 alkyl groups, C6-C24 (hetero)aryl groups, C7-C24 alkyl(hetero)aryl groups and C7-C24 (hetero)arylalkyl groups and wherein the alkyl groups, (hetero)aryl groups, alkyl(hetero)aryl groups and (hetero)arylalkyl groups are optionally substituted, wherein two substituents R15 may be linked together to form an optionally substituted annulated cycloalkyl or an optionally substituted annulated (hetero)arene substituent, and wherein R16 is independently selected from the group consisting of hydrogen, halogen, C1-C24 alkyl groups, C6-C24 (hetero)aryl groups, C7-C24 alkyl(hetero)aryl groups and C7-C24 (hetero)arylalkyl groups;
Y2 is C(R31)2, O, S, S(+)R31, S(O)R31, S(O)═NR31 or NR31, wherein S) is a cationic sulphur atom counterbalanced by B3, wherein B(−) is an anion, and wherein each R31 individually is R15 or a connection with Q2 or D, connected via L;
u is 0, 1, 2, 3, 4 or 5;
u′ is 0, 1, 2, 3, 4 or 5, wherein u+u′=0, 1, 2, 3, 4, 5, 6, 7 or 8;
v=an integer in the range 8-16.

### Claim 18 (depends on 16)

The glycoprotein-conjugate according to claim 16, wherein Q2 is reactive in a cycloaddition.

### Claim 19 (depends on 16)

The glycoprotein-conjugate according to claim 16, wherein the payload D is selected from an active substance, a reporter molecule, a polymer, a solid surface, a hydrogel, a nanoparticle, a microparticle and a biomolecule.

### Claim 20 (depends on 16)

A process for preparing a glycoprotein-conjugate, comprising reacting a glycoprotein according to structure (1a) according to claim 16, with a payload having structure D-F2 or F2-L2-(D), wherein F2 is reactive towards the chemical handle Q2 in a conjugation reaction and wherein L2 is a linker and x is an integer in the range of 1-4.

### Claim 21 (depends on 16)

A pharmaceutical composition comprising the glycoprotein-conjugate according to structure (1b) according to claim 16 and a pharmaceutically acceptable carrier.

### Claim 22 (depends on 16)

A method of treating cancer, comprising administering to a subject in need thereof a glycoprotein-conjugate according to structure (1b) according to claim 16.

### Claim 23

A process for preparing a protein-conjugate, comprising:
(a) providing a mutant protein, which is in its native form unreactive towards oxidative enzymes capable of oxidizing tyrosine, but is rendered reactive towards such enzymes by providing a mutated form of the protein, wherein a tyrosine residue is introduced at a non-native position of the amino acid sequence of the protein where it is reactive towards oxidative enzymes capable of oxidizing tyrosine;
(b) converting the phenol moiety of the tyrosine residue into an ortho-quinone moiety by contacting the protein with an oxidative enzyme capable of oxidizing tyrosine;
(c) reacting the ortho-quinone moiety with an alkene or alkyne compound via a [4+2]cycloaddition, wherein the compound comprises a (hetero)cycloalkene or (hetero)cycloalkyne moiety and (i) a chemical handle to further modify the compound with a payload, or (ii) a payload.

### Claim 24

A protein-conjugate according to structure (1a) or (1b):
wherein:
Pr is a protein;
Z1 comprises structure (Za) or (Zb):
wherein the carbon labelled with * is directly connected to the peptide chain of the glycoprotein at an amino acid which is in the native form of the protein not a tyrosine residue, and both of the carbon atoms labelled with ** are connected to L, and the bond depicted as is a single bond or a double bond;
L is a linker;
x is an integer in the range of 1-4;
y is an integer in the range of 1-4;
Q2 is a chemical handle that is reactive towards an appropriately functionalized payload;
D is a payload.

### Claim 25 (depends on 24)

The protein-conjugate according to claim 24, wherein the amino acid to which the connecting group Z1 is connected is located at a position where a tyrosine residue is reactive towards oxidative enzymes capable of oxidizing tyrosine.

### Claim 26 (depends on 24)

The protein-conjugate according to claim 24, wherein Pr is a mutant protein which is in its native form unreactive towards oxidative enzymes capable of oxidizing tyrosine, but is rendered reactive towards such enzyme by providing a mutated form of the protein, wherein a tyrosine residue is introduced at a non-native position in a position of the amino acid sequence of the protein where it is reactive towards oxidative enzymes capable of oxidizing tyrosine.
